This study group aimed to revise the 2017 international consensus guidelines for the
management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas, and …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

Pancreatic ductal adenocarcinoma is most frequently detected at an advanced stage. Such
late detection restricts treatment options and contributes to a dismal 5-year survival rate of 3 …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Background & Aims It has been a challenge to select treatment for patients with pancreatic
ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted …

Background & Aims Long-term outcomes of patients with branch-duct intraductal papillary
mucinous neoplasms (IPMNs), particularly those after 5 years of surveillance, have not been …

Pancreatic cystic neoplasms (PCN) are a heterogeneous group of pancreatic cysts that
include intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, serous cystic …

Pancreatic cancer usually results in poor survival with limited options for treatment, as most
affected individuals present with advanced disease. Early detection of preinvasive …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …